ZLB Behring Releases Plasma Derivatives Anthrobin P1500.Tokyo, Japan, Apr 17, 2006 - (JCN) - ZLB Behring announced on April 14 that it has launched Anthronbin P1500 Injection, a new item in its plasma derivatives series. The new product, which is a human antithrombin antithrombin I fibrin, referring to its capacity to adsorb thrombin and thus neutralize it. antithrombin III a plasma a of the serpin family that inactivates thrombin and also inhibits certain coagulation factors and kallikrein. Inherited deficiency is associated with recurrent deep vein thrombosis and pulmonary emboli; the complications are prevented and treated with a preparation of antithrombin III from pooled human III concentrate, is indicated for the treatment of thrombosis associated with congenital antithrombin III deficiency as well as disseminated intravascular intravascular /in·tra·vas·cu·lar/ (in?trah-vas´ku-lar) within a vessel.in·tra·vas·cu·lar (  n tr coagulation. Available in 1500 IU per syringe, the product helps simplify the drug preparation process while reducing the burden on medical staff and the risk of infection and contamination. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion